-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, Shiyao Group (01093.HK) announced that a randomized, multi-center, open-label phase III clinical trial evaluating SYS 6043 (B7-H3-ADC) developed by the group compared chemotherapists selected by researchers to treat advanced platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants has officially launched at the first center in China.

Zhitongcaijing·07/16/2026 11:33:28
Listen to the news
According to Zhitong Finance App, Shiyao Group (01093.HK) announced that a randomized, multi-center, open-label phase III clinical trial evaluating SYS 6043 (B7-H3-ADC) developed by the group compared chemotherapists selected by researchers to treat advanced platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants has officially launched at the first center in China.